Eli Lilly And Co (NYSE:LLY) Shares Bought by Eagle Asset Management Inc.

Eagle Asset Management Inc. grew its stake in shares of Eli Lilly And Co (NYSE:LLY) by 1,392.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 251,136 shares of the company’s stock after acquiring an additional 234,305 shares during the period. Eagle Asset Management Inc.’s holdings in Eli Lilly And Co were worth $28,084,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of LLY. Bessemer Group Inc. raised its holdings in Eli Lilly And Co by 2,354.5% in the 2nd quarter. Bessemer Group Inc. now owns 569,510 shares of the company’s stock valued at $63,096,000 after acquiring an additional 546,307 shares during the last quarter. Cedar Capital LLC raised its holdings in Eli Lilly And Co by 17.5% in the 2nd quarter. Cedar Capital LLC now owns 2,459 shares of the company’s stock valued at $272,000 after acquiring an additional 367 shares during the last quarter. Assetmark Inc. raised its holdings in Eli Lilly And Co by 13.9% in the 2nd quarter. Assetmark Inc. now owns 410,334 shares of the company’s stock valued at $45,461,000 after acquiring an additional 50,087 shares during the last quarter. Haverford Trust Co. raised its holdings in Eli Lilly And Co by 60.3% in the 2nd quarter. Haverford Trust Co. now owns 6,418 shares of the company’s stock valued at $711,000 after acquiring an additional 2,414 shares during the last quarter. Finally, Naples Global Advisors LLC raised its holdings in Eli Lilly And Co by 1.1% in the 2nd quarter. Naples Global Advisors LLC now owns 15,591 shares of the company’s stock valued at $1,727,000 after acquiring an additional 170 shares during the last quarter. Institutional investors own 77.22% of the company’s stock.

Shares of NYSE LLY traded up $0.76 during trading on Friday, hitting $113.53. 2,190,598 shares of the company traded hands, compared to its average volume of 7,683,282. Eli Lilly And Co has a 1 year low of $101.36 and a 1 year high of $132.13. The company has a 50-day moving average price of $110.61 and a 200-day moving average price of $112.67. The firm has a market capitalization of $106.81 billion, a P/E ratio of 20.46, a P/E/G ratio of 1.82 and a beta of 0.16. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 4.09.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings data on Wednesday, October 23rd. The company reported $1.48 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.43 by $0.05. Eli Lilly And Co had a net margin of 35.10% and a return on equity of 107.99%. The company had revenue of $5.48 billion during the quarter, compared to analysts’ expectations of $5.50 billion. During the same period in the previous year, the company earned $1.39 EPS. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. Research analysts predict that Eli Lilly And Co will post 5.78 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a $0.645 dividend. The ex-dividend date is Thursday, November 14th. This represents a $2.58 dividend on an annualized basis and a yield of 2.27%. Eli Lilly And Co’s payout ratio is currently 46.49%.

LLY has been the subject of several analyst reports. UBS Group cut their price target on Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a report on Thursday, October 17th. Bank of America started coverage on Eli Lilly And Co in a report on Wednesday, October 16th. They issued a “buy” rating and a $133.00 price target for the company. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Eli Lilly And Co currently has a consensus rating of “Buy” and a consensus price target of $130.03.

In other Eli Lilly And Co news, SVP Stephen F. Fry sold 9,452 shares of the company’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $115.00, for a total value of $1,086,980.00. Following the completion of the transaction, the senior vice president now directly owns 100,211 shares of the company’s stock, valued at approximately $11,524,265. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Alfonso G. Zulueta sold 4,500 shares of the company’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $117.00, for a total transaction of $526,500.00. Following the completion of the transaction, the senior vice president now directly owns 33,806 shares of the company’s stock, valued at $3,955,302. The disclosure for this sale can be found here. Over the last three months, insiders acquired 8,405 shares of company stock valued at $909,004 and sold 614,373 shares valued at $70,546,895. Corporate insiders own 0.11% of the company’s stock.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: Cryptocurrencies

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.